During the pilot trial production program, the product defect rate spiked to 4.73%, breaching our maximum internal target threshold of <4.0%. A physical Pareto analysis isolated a critical contribution: 136 pieces of assembly gap defects occurred during Shift 2, accounting for 38.7% of the entire program’s failures. This spike forced frontline teams into continuous, volatile process adjustments across production shifts.

Rather than treating this as a superficial machine or operator error, I needed to deconstruct the system’s root cause and permanently stabilize the manufacturing parameters before mass-production rollout. The objective was to bring the defect rate down to target levels by driving cross-functional alignment across Engineering, Production, and QA squads.

I bypassed assumptions and deployed a rigorous *5-Why First-Principles analysis* to map out the exact chain of failure

• Tracing the Paradox: Discovered that Shift 2 operators adjusted ultrasonic welding parameters because quality controllers flagged assembly gap deviations[cite: 3].
• Isolating the Variance: Uncovered that the physical IPQC plan demanded a rigid gap constraint of ≤0.3 mm, whereas the customer-approved buy-off limit sample explicitly permitted up to 0.4 mm.
• Identifying the System Break: Pinpointed the failure to document control infrastructure—the updated buy-off metrics had not been synchronized into the active IPQC sheet prior to shift handover[cite: 3].
• Enforcing Hard Poka-Yoke Gates: Rewrote the operational gatekeeping protocol with two mandatory Standardized Work rules:
  • CB-MCD-7-001: Legally hardcoded that the latest approved buy-off limit sample supersedes document discrepancies[cite: 3]. • CB-MCD-7-003: Frozen system logic preventing any product trial from shifting handovers unless buy-off limits, IPQC rules, and tooling data are verified as a complete package.

The root cause was entirely a governance failure, not a mechanical or execution failure. By stabilizing document synchronization gates, the next consecutive trial rollout dropped its defect rate down to *3.07%* (a **35% net optimization**), successfully pulling the total multi-market program baseline back under our required corporate KPI target to *3.90%*[cite: 3].